US EditionPublished • loading... • Updated
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- Ascletis Pharma Inc. completed enrollment of 100 participants in its 13-week U.S. Phase II study of ASC30 for treating type 2 diabetes mellitus .
- ASC30's first approved indication is for obesity, and type 2 diabetes is its second indication under study.
- The Phase II study is randomized, double-blind, placebo-controlled, and conducted across multiple U.S. sites.
- Topline data from the T2D Phase II study are expected in the third quarter of 2026.
Insights by Ground AI
25 Articles
25 Articles
Ascletis completes enrolment in US Phase II Study of ASC30
Ascletis Pharma has completed enrolment in its 13-week US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026.The Phase II study is a 13-week, randomised, double-blind, pla…
Coverage Details
Total News Sources25
Leaning Left5Leaning Right3Center7Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 33%
C 47%
R 20%
Factuality
To view factuality data please Upgrade to Premium
